palvella Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
353 W Lancaster Ave Ste 200, Wayne, Penn...Phone Number
(484) 253-1461Website
www.palvellatx.comRevenue
-Stock Symbol
PVLAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients affected by serious rare genetic skin disorders and vascular diseases that currently have limited or no approved treatment options. The company focuses on advancing precision medicines designed to address conditions that significantly affect patients' quality of life while often lacking effective therapeutic alternatives. Through scientific innovation, clinical research, and targeted drug development, Palvella Therapeutics seeks to transform the treatment landscape for underserved patient populations living with debilitating dermatological and vascular disorders.Explore more
palvella Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is palvella Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if palvella Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at palvella Therapeutics
Check out if palvella Therapeutics is spiking on competitors!
Click to see if palvella Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
palvella Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when palvella Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on palvella Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once palvella Therapeutics has new funding data
Recommended Actions
Find VP level buyers at palvella Therapeutics
Find 3 more new buyers
Compare Similar Companies to palvella Therapeutics
Compare insights from companies similar to palvella Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
palvella Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
palvella Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about palvella Therapeutics.
palvella Therapeutics financials insights
Gather financial insights about palvella Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$9.2M
2020
Series C
$45M
2023
Series D
$37.7M
palvella Therapeutics Tech Stack
A closer look at the technologies used by palvella Therapeutics
See more technologies
Most Recent Scoops
Project
maintains a physical library of nearly 3,000 approved small molecule drugs from the US, Europe, and Japan the majority of which are generic and screens this library as the first step in any rare disease project to remove time and funding barriers to treatment access and to generate new therapeutic hypotheses.
Pharmaceuticals
Project
palvella Therapeutics is completing pre-IND work and IND-enabling studies for QTORIN pitavastatin, its second product candidate, which is intended to be studied in disseminated superficial actinic porokeratosis, a serious rare genetic disease, with a study initiation expected later this year.
Medical Research, Pharmaceuticals
Project
palvella Therapeutics has announced plans to initiate a Phase III study for QTORIN rapamycin in cutaneous venous malformations in the current year, with the Phase III study design to be announced by year-end following FDA interactions.
Medical Research, Pharmaceuticals, Clinical Operations
Project
palvella Therapeutics has reported that its Phase III pivotal study of QTORIN rapamycin in microcystic lymphatic malformations met its primary, key secondary, and all pre-specified secondary endpoints, with 95% of patients showing improvement and 86% rated as much improved or very much improved on the clinician assessment scale.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals
palvella Therapeutics News & Media
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor cPalvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S.Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord GePalvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding palvella Therapeutics
Sign Up For FreeTo access detailed company insights
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients affected by serious rare genetic skin disorders and vascular diseases that currently have limited or no approved treatment options. The company focuses on advancing precision medicines designed to address conditions th... Read More
